|
|
Volumn 96, Issue 14, 2004, Pages 1061-
|
|
FDA panel scrutinizes safety of anti-anemia drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
ANTINEOPLASTIC AGENT;
HEMOGLOBIN;
NEORECORMAN;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PLACEBO;
RECOMBINANT ERYTHROPOIETIN;
DRUG DERIVATIVE;
ERYTHROPOIETIN;
ANEMIA;
BLOOD TRANSFUSION;
CANCER PATIENT;
CANCER RECURRENCE;
CANCER SURVIVAL;
CARDIOVASCULAR DISEASE;
CLINICAL PRACTICE;
CLINICAL TRIAL;
DISEASE COURSE;
DRUG LABELING;
DRUG MARKETING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HEMATOCRIT;
HUMAN;
MALIGNANT NEOPLASTIC DISEASE;
NOTE;
PRIORITY JOURNAL;
RISK ASSESSMENT;
THROMBOSIS;
TREATMENT OUTCOME;
ADVERTIZING;
ARTICLE;
CONTROLLED CLINICAL TRIAL;
MULTICENTER STUDY;
NEOPLASM;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
UNITED STATES;
ADVERTISING;
ANEMIA;
ERYTHROPOIETIN;
ERYTHROPOIETIN, RECOMBINANT;
HEMATINICS;
HUMANS;
MULTICENTER STUDIES;
NEOPLASMS;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 3242679702
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/96.14.1061 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|